1)Barbazetto I, Burdan A, Bressler NM et al:Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin:fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP report No. 2. Arch Ophthalmol121:1253-1268, 2003
2)Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy(TAP)Study Group:Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198-207, 2001
3)Verteporfin in Photodynamic Therapy Study Group:Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration:two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization―verteporfin in photodynamic therapy report 2. Am J Ophthalmol131:541-560, 2001
4)Japanese Age-Related Macular Degeneration Trial(JAT)Study Group:Japanese age-related macular degeneration trial:1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049-1061, 2003
5)Schmidt-Erfurth UM, Michels S:Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporphin. Ophthalmology 110:1306-1314, 2003
6)Schmidt-Erfurth U, Laqua H, Schlotzer-Schrebard U et al:Histopathological changes following photodynamic therapy in human eye. Arch Ophthhalmol120:835-844, 2002
7)Schmidt-Erfurth U, Schlotzer-Schrebard S, Cursiefen C et al:Influence of photodynamic therapy on expression of vascular endothelial growth factor(VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci44:4473-4480, 2003
8)Gollnick SO, Evans SS, Baumann H et al:Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88:1772-1779, 2003
9)Spaide RF, Sorenson J, Maranan L:Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517-1525, 2003
10)Spaide RF, Sorenson J, Maranan L:Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301-304, 2005
11)Rechtman E, Danis RP, Pratt LM et al:Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88:344-347, 2004
12)日本ポリープ状脈絡膜血管症研究会:ポリープ状脈絡膜血管症の診断基準.日眼会誌 109:417-427,2005
13)井上 真:トリアムシノロン局所投与後の眼内動態.あたらしい眼科 21:1043-1048,2004
14)Uyama M, Wada M, Nagai Y et al:Polypoidal choroidal vasculopathy:natural history. Am J Ophthalmol 133:639-648, 2002
15)左近允徳啓・森隆三郎・山西朗子・他:ポリープ状脈絡膜血管症のインドシアニングリーン蛍光眼底造影所見と黄斑所見の関係.臨眼 58:1477-1481,2004
16)Yuzawa M, Mori R, Haruyama M:A Study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 47:379-384, 2003
17)Silva RM, Figueira J, Cachulo ML et al:Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 28:2005[Epub ahead of print]
18)Chan WM, Lam DS, Lai TY et al:Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy:one-year results of a prospective case series. Ophthalmology 111:1576-1584, 2004
19)埜村裕也・安宅伸介・和田園美・他:硝子体切除眼におけるトリアムシノロン硝子体内投与後の早期眼圧上昇.あたらしい眼科 22:1258-1288,2005